Alnylam licenses intellectual property in RNA interference.Alnylam Pharmaceuticals, Inc. (Cambridge, MA) has signed a licensing agreement with Stanford University (Stanford, CA) for intellectual property related to the method for inducing gene silencing through RNAi in adult mammals. The licensing of this additional intellectual property expands Alnylam's leadership position in the fundamental patents, technology and know-how that underlie the discovery, development and commercialization of RNAi-based therapeutics.
Alnylam executed a co-exclusive therapeutic license from Stanford University for the RNA interference RNA interference
A process in which the introduction of double-stranded RNA into a cell inhibits the expression of genes. patent application and related technology which is based on the research of Dr. Mark Kay, Dr. Anton McCaffrey and colleagues at the Stanford University School of Medicine Stanford University School of Medicine is affiliated with Stanford University and is located at Stanford University Medical Center in Stanford, California, adjacent to Palo Alto and Menlo Park. . This intellectual property encompasses the demonstration that delivery of synthetic small interfering RNA Small interfering RNA (siRNA), sometimes known as short interfering RNA or silencing RNA, are a class of 20-25 nucleotide-long double-stranded RNA molecules that play a variety of roles in biology. molecules to an adult mammal can induce in vivo in vivo /in vi·vo/ (ve´vo) [L.] within the living body.
Within a living organism.
in vivo adv. silencing of a specific target gene, thereby a basis for the systemic administration of RNAi-based therapies in mammals.
"The addition of this intellectual property from Stanford, when combined with our existing portfolio of the fundamental patents in the field of RNAi, further strengthens Alnylam's clear leadership in worldwide intellectual property for the development of RNAi-based therapeutics," said Dr. John Maraganore, president and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Alnylam. "We continue to fortify for·ti·fy
v. for·ti·fied, for·ti·fy·ing, for·ti·fies
To make strong, as:
a. To strengthen and secure (a position) with fortifications.
b. To reinforce by adding material. our intellectual property foundation in RNAi that uniquely positions us to develop and commercialize a new class of medicines."
Alnylam is a leading company in the emerging field of RNA interference (RNAi) whose vision is to Harness a Revolution in Biology for Human Health. Growing from its foundation as the world's first company focused on RNAi-based therapeutics, the company is built around the leading capabilities of its two operating units, Alnylam Pharmaceuticals, and Ribopharma (Kulmbach, Germany). Over the last several years, RNAi has been identified as a fundamental cellular mechanism for gene silencing. The company's leadership in the field of RNAi is supported by its preeminent founders and advisors and its strengths in fundamental patents, technology, and know-how that underlie the commercialization of RNAi-based therapeutics. The company's focus is to discover, develop, and commercialize therapeutic products based on RNAi for a broad range of therapeutic indications including viral, oncologic, metabolic, CNS See Continuous net settlement.
See continuous net settlement (CNS). and autoimmune diseases Autoimmune diseases
A group of diseases, like rheumatoid arthritis and systemic lupus erythematosus, in which immune cells turn on the body, attacking various tissues and organs.
Mentioned in: Complement Deficiencies, Premature Menopause . The company's mission is to lead research in the field of RNAi, to build the leading pipeline of RNAi-based therapeutics, and to emerge as business leaders.
Alnylam Pharmaceuticals, Inc.